Large Cap Biopharma Stocks Performance 2019: Interim Report 4/25
Large Cap Biopharma Stocks Review Ongoing Through Q1 Earnings Small and Mid-Caps Outperform Large Caps YTD: XBI up 21 % YTD vs IBB up 8.19% QQQ up 27%. Rally emerging today on oversold condition in biotech. We will update this valuation review since the political onslaught and sell-off from...
Biotech Wreck: What To Look For Next…Update-3 earnings reports
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains 14.4%, Revenues gain 0.4%. BMY...
Choppy Week in Healthcare with Drug Pricing Issues Yet Again: Update-2-SELL-OFF
Update-2 10:45a 4/17...XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1...NASDAQ ekes out small gains but large cap biotechs take another hit with IBB down 1% to...
Biotech Hits New Highs for 2019:The Trends are Bullish…Update-3 at Sell-Off
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and "affordability board." See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks broadly down on. "Red Screen Day". 4/11/19...
High Volatility Among Individual stocks with Few Trends…Update-4
Update-4. 4/3 11:45A... Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3 4/2/19... Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91% NTLA 4.9% MGTX up 4.6%, etc. Most Mid-Caps green: BPMC up...